Nonsteroidal Anti-inflammatory Drugs and Aspirin for the Prevention of Colorectal Adenomas and Cancer: A Systematic Review

Diseases of the Colon and Rectum

Volumn 47, Issue 5, 2004, Pages 665-673

  Asano, T K ^a   McLeod, R S ^b  

^a Institut national du cancer du Canada   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Adenomas; Aspirin; Chemoprevention; Colorectal neoplasms; Nonsteroidal anti inflammatory drugs; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC;

ADENOMATOUS POLYP; CANCER PREVENTION; CLINICAL TRIAL; COLON ADENOMA; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG USE; FAMILIAL ADENOMATOUS POLYPOSIS; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; RECTUM ADENOMA; REVIEW; SIDE EFFECT;

ADENOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLORECTAL NEOPLASMS; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY; RANDOMIZED CONTROLLED TRIALS;

EID: 2342594552     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10350-003-0111-9     Document Type: Review

References (45)

1. Canadian Cancer Society. Canadian Cancer Statistics, 2002. Available at: http://www.cancer.ca. Accessed February 2003.
2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org. Accessed February. 2003.
3. Trends in screening for colorectal cancer: United States, 1997 and 1999. MMWR 2001;50:162-6
4. Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997;89:1406-22
5. Do Arber N. NSAIDs prevent colorectal cancer. Can J Gastroenterol 2000;14:299-307
6. Hawk E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 1999;86:1731-43
7. Paganini-Hill A. Aspirin and the prevention of colorectal cancer: a review of the evidence. Semin Surg Oncol 1994;10:158-64
8. Turner D, Berkel HJ. Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer. Can Med Assoc J 1993;149:595-602
9. Vainio H, Morgan G, Kleihues P. An international evaluation of the cancer-preventive potential of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 1997;6:749-53
10. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6
11. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14
12. Dannenberg AJ, Zakim D. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. Semin Oncol 1999;26:499-504
13. Gupta RA, Dubois RN. Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer. Ann Acad Sci 2000;910:196-206
14. Clarke M, Oxman AD. Cochrane reviewers' handbook 4.1.6
15. National Cancer Institute. Common toxicity criteria. Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed May 12, 2003.
16. Seow-Choen F, Pappalardo G, Maiani G. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis. Br J Surgery 1996;83:1763-6
17. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-9
18. Burns J, Chapman PD, Mathers J, et al. The protocol for a European double-blind trial of aspirin and resistant starch in familial adenomatous polyposis: the CAPP study. Concerted Action Polyposis Prevention. Eur J Cancer 1995;31A:1385-6
19. Burns J, Chapman PD, Mathers J, Bishop DT, Lynch H. CAPP2: an international controlled trial of aspirin and resistant starch in carriers of HNPCC. J Med Genet 1997; 34:S53
20. Anonymous. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
21. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. B-Carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999;91:2102-6
22. The steering committee of the Physicians' Health Group. Preliminary report: findings from the aspirin component of the ongoing physicians' health study. N Engl J Med 1988;318:263-4
23. Benamouzig R, Yoon H, Little J, et al. APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings. Eur J Cancer Prev 2001;10:327-35
24. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1220-4
25. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-9
26. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-36
27. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9
28. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90
29. Ladenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108:1083-7
30. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52
31. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6
32. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-9
33. Winawer SJ, Zauber AG, Ho MN. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993;329:1977-81
34. Winawer SJ. Natural history of colorectal cancer. Am J Med 1999;106:3S-6S
35. A multi-centre double blind randomised controlled trial of aspirin and/ or folate supplementation for the prevention of recurrent colorectal adenomas. UKCCCR National Register of Cancer Trials Web site. Available at: http://www.ctu.mrc.ac.uk/ukcccr/home.asp. Accessed October 30, 2003.
36. Trial update and news. Available at: http://www.ncl.ac.uk/capp/ptrial.htm. Accessed October 30, 2003.
37. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study. J Womens Health 2000;9:19-27
38. U.S. Preventive Task Force. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann Intern Med 2002;136:161-72
39. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9
40. Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology 2002;122:78-84
41. Ladabaum U, Chopra CL, Huanga G, Scheiman JM, Chernew ME, Fendrick AM. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2001;135:769-81
42. Cruz-Correa M, Hylinda LM, Romans KE, Booker SV, Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002;122:641-5
43. Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 1994;107:854-7
44. Thorson AG, Lynch HT, Smyrk TC. Rectal cancer in FAP patient after sulindac. Lancet 1994;343:180
45. Keller JJ, Offerhaus GJ, Drillenburg P, et al. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Clin Cancer Res 2001;7:4000-7